To understand last weeks PR read the following written by a guy with a PHD who understands this information well;
Sensitivity and specificity tell you how often the device makes a mistake. Great sensitivity means you catch all of the cases (you don't miss people who have the disease.) Great specificity means you don't accidentally tell people they have the disease when they don't.
That means MRI is really good at not telling people they have the disease, when they don't, but it misses a few cases. TAEUS is really good at finding all the cases, but accidentally tells people they have the disease when they don't.
Biopsy, is good at both, but means having someone poke a hole in you and pull out a piece of liver.
This is really good because we now have two complementary methods to screen for the disease. TAEUS will catch them all, and if they're not sure, they'll send them to MRI to confirm.
We actually don't care too much about accuracy of patients with less than 5% liver fat anyhow - they clearly don't need treatment.
"The Investors's Chief Problem--and even his worst enemy--is likely to be himself"
---Benjamin Graham
Recent NDRA News
- ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/28/2024 08:05:00 PM
- ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 • Business Wire • 03/21/2024 12:00:00 PM
- ENDRA Life Sciences Installs First TAEUS System in the UK • Business Wire • 02/27/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:00:45 PM
- New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System • Business Wire • 02/21/2024 01:00:00 PM
- ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe • Business Wire • 02/14/2024 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/29/2023 10:07:32 PM
- ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology • Business Wire • 11/29/2023 01:00:00 PM
- ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference • Business Wire • 11/27/2023 01:00:00 PM
- ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update • Business Wire • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:02:23 PM
- ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents • Business Wire • 11/08/2023 01:00:00 PM
- ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023 • Business Wire • 11/07/2023 09:05:00 PM
- ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023 • Business Wire • 11/06/2023 01:00:00 PM
- Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023 • Business Wire • 09/07/2023 12:00:00 PM
- ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA • Business Wire • 08/30/2023 12:00:00 PM
- ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents • Business Wire • 08/23/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:45:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:13:52 PM
- ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update • Business Wire • 08/14/2023 08:05:00 PM
- ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA • Business Wire • 08/14/2023 05:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:01:23 PM
- ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023 • Business Wire • 08/01/2023 12:00:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM